HSHasan Satış

Hasan Satış

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Satış has a total of 317 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of symptomatic extra-articular manifestations of rheumatoid arthritis on disease activity and patient-reported outcomes: a cross-sectional and observational study

    by Ahmet Oruç, Hasan Satış, Merve Oruç, Reyhan Bilici, Abdurrahman Tufan, Mehmet Akif Öztürk

    Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints but also has extra-articular manifestations. Extra-articular manifestations (EAMs) in RA encompass a wide range of clinical findings that may significantly affect patients’ quality of life. This study aimed to compare daily life, social function, and work productivity between RA patients with and without EAMs. In this study, we aimed to determine the differences in daily life, social life, and work between patients with and without EAM. Methods: This cross-sectional and observational study included 402 RA patients (2010 ACR-EULAR). EAM was defined as systemic symptoms and organ involvement occurring outside of the joint findings caused by RA. The presence of EAM was grouped as symptomatic/asymptomatic. Patients were evaluated once during the study period in an outpatient setting. Patients completed the Health Assessment Questionnaire (HAQ), Short Form-36 (SF-36), and Work Productivity and Activity Impairment: General Health (WPAI: GH) forms under clinician observation. Continuous variables were compared using the Mann–Whitney U test and Independent Samples T-test, while Fisher’s exact test or chi-square test was used for categorical variables. The significance level was set at 5% ( p < 0.05). Results: The study included 402 patients. 325 (80.8%) were female, with a median (IQR) age of 56 (47–64.25) and a mean±standard deviation (SD) disease duration of 9.7 ± 8.6 years. EAM was present in 200 patients. Patients were classified as having symptomatic EAM (sEAM) (n = 81), asymptomatic EAM (asEAM) (n = 119), and no EAM (n = 202). The median age was 60 (54.5–67), and the median age at diagnosis was 49 (39.5–58) in the sEAM group, which had the highest values (p:<0.001 and p:0.003, respectively). Peripheral neuropathy detected in 24 (29.6%) patients was the most common symptomatic EAM, while keratoconjunctivitis sicca detected in 44 (36.9%) patients was the most common asymptomatic EAM. In sEAM patients, HAQ mean ± SD was 0.92 ± 0.73, while in non-EAM patients it was 0.68 ± 0.65, p = 0.021. In SF-36 results, physical function, social function, role physical, vitality, and mental health were statistically significantly lower in patients with sEAM compared to other groups. The percentage of working patients was higher at 28.2% in those without EAM, p:0.010. Absenteeism, mean ± SD, was higher in the sEAM group at 12.8 ± 28.1, p: 0.037, and activity impairment was also higher in sEAMs at mean ± SD 44.2 ± 29.1, p:0.025. Conclusions: Regardless of RA disease activity, patients with sEAM experience negative impacts on both their daily and social lives as well as their work life. Symptomatic EAMs are associated with significant impairment in quality of life and work productivity, independent of traditional disease activity measures. Clinicians should therefore systematically assess and manage these manifestations as an integral component of RA care.

  • Open Access

    From Conventional to Advanced Therapies: A National Health Registry Report (2016-2022) on DMARDs in Rheumatoid Arthritis Treatment in Turkey

    by Naim Ata, Hasan Satış, Orhan Küçükşahin, Erdem Karabulut, Gizem Ayan, Abdulsamet Erden, Emre Bilgin, Berkan Armağan, Duygu Tecer, Hakan Babaoğlu, et al.

    Objective: There are national and international guidelines on the optimal use of disease-modifying anti-rheumatic drugs. In this study, we aimed to provide critical insights into the real-world efficacy and adherence of these DMARDs, providing a data-driven basis for optimizing treatment paradigms for RA within the national healthcare framework. Methods: This nationwide cohort study utilized data from the Turkish Ministry of Health National Electronic Database, known as E-Pulse between January 2016 and December 2022. In this analysis, cases of RA were identified using ICD-10 codes two times at least 30 days apart Treatment prescriptions were recorded based on their prescription at baseline and follow-up. Results: There were a total of 347,902 RA (79.5% female) patients in the E-Pulse system. The mean (SD) age of RA patients was 59.1 (14.8) years Methotrexate and sulfasalazine (35.1% vs 30.5%, OR 95% CI 0.81 usage was more common in men and hydroxychloroquine was more common in women 46.764 (13.4%) patients were prescribed bDMARD and/or tsDMARD 494.499 times. AntiTNF drugs are the most commonly prescribed drugs. This is followed by B-cell blockers, JAK inhibitors, anti-IL6 and T-cell blockers. Conclusion: Turkish national health database highlights the widespread use of synthetic DMARDs in treating rheumatoid arthritis (RA). While traditional DMARDs like methotrexate and hydroxychloroquine are favored the cautious use of advanced therapies, particularly anti-TNFs, suggests a potential for optimizing treatment protocols.


  • Open Access

    A nationwide study: prevalence of rheumatoid factor and anti- citrullinated peptide positivity and their contribution to rheumatoid arthritis diagnosis

    by Hasan Satiş, Abdulsamet Erden, Emre Bi̇lGi̇n, Gi̇zEm Ayan, Berkan Armağan, Duygu Tecer, Alper Sari, Umut Kalyoncu, Murat Çağlayan, Mustafa Mahi̇r Ülgü, et al.

    Aim: Rheumatoid factor (RF) and Anti Citrullinated Peptide (anti-CCP) is specific for rheumatoid arthritis (RA) diagnosis. However they could be positive in other disease and even healthy populations. It was aimed to investigate the prevalence of positive RF and anti-CCP antibodies in persons admitted to hospital for any reason and on a national scale.Material and Method: The National Electronic Health Database, which contains the clinical records of over eighty million people, is used to design this multi-center, retrospective cohort study. The subjects included in the study were divided into age groups in 10-year periods. RA cases were identified by using ICD-10 codes that included M05,M06, M08,and their subgroups. RF and anti-CCP positivity were evaluated in terms of their contribution to the risk of being diagnosed with RA, with the change according to age and genderResults: During the 1.1.2018-31.12.2021 period, 13.918.072 RF tests were performed in 11.849.440 people, whereas 1.183.607 anti-CCP test were performed in 1.020.967 people. 797.089 people had at least once both tests performed. RF positivity rate in patients who only requested RF test was 14.72% and it was 35.04% for anti-CCP positivity in only requested anti-CCP tests. The rate of concomitant RF and anti-CCP positivity was 22.56%.RA diagnosis is made in in 27.8% of RF-positive people, in 39.73% of anti-CCP-positive people and in %56.6 of co RF and anti CCP positive people. RF positivity and concomitant RF and anti-CCP positivity increased with the age and more common in females.Conclusion: RF and anti-CCP positivity could be seen in a healthy population with female predominance. As the age increases, the risk of RF positivity is increased, however anti –CCP positivity does not change. Concomitant RF and anti-CCP positivity has the highest risk of RA development with respect to either antibody positivity alone.


  • Open Access

    ASSESSMENT OF HAEMOPHILIC ARTHROPATHY IN PATIENTS WITH SEVERE HEMOPHILIA USING THE HEMOPHILIA EARLY ARTHROPATHY DETECTION WITH ULTRASOUND (HEAD-US) SCORE AND THE HEMOPHILIA JOINT HEALTH SCORE (HJHS) BY DIFFERENT CAREGIVERS

    by Emine Yılmaz Orulluoğlu, Zühre Kaya, Hasan Satış, Merve Yazol, Serap Kirkiz, Ülker Koçak

    The Journal of Kırıkkale University Faculty of Medicine | Volume: 26 Issue: 1

  • The assessment of hyposalivation and its impact on mouth disability in systemic sclerosis patients

    by Aslihan Avanoglu Guler, Hazan Karadeniz, Reyhan Bilici, Hasan Satış, Hakan Babaoğlu, Nuh Ataş, Hamit Küçük, Berna Göker, Seminur Haznedaroğlu, Mehmet Akif Öztürk, et al.

  • Exocrine pancreatic dysfunction in systemic sclerosis and primary Sjogren’s syndrome patients

    by Hasan Satış, Burak Arslan, Serdar Can Güven, Reyhan Bilici Salman, Hakan Babaoğlu, Nuh Ataş, Aslıhan Avanoğlu Güler, Hazan Karadeniz, Berna Göker, Şeminur Haznedaroğlu, et al.

  • Aile Hekimliğinde Güncel Yaklaşımlar

    by Mina Lara Akıncı, Cemil Işık Sönmez, Eda Kuran, Zerrin Gamsızkan, Pelin Yıldırım, Gaye Didem Çabukoğlu, Ersin Akpınar, Seher Baysan Arslan, Seda Özen Zunal, Emine Füsun Akyüz Çim, et al.

    Aile hekimliği tıp disiplinin özelliklerini, ilkelerini ve temel değerlerini detaylarıyla bulabileceğiniz bölümlerin yanında, klinik uygulamalarda izlenecek yollar ve kılavuzların eşlik ettiği güncel bilgileri sizlerle paylaşmayı hedefledik. Aile hekimliğinin, yaş, cinsiyet, hastalık ayırt etmeksizin sunduğu sağlık bakımına ek olarak koruyucu sağlık hizmetlerinin prekonsepsiyonel dönemden bireyin ölümü sonrasındaki aile bireylerinin durumuna kadar geniş konu yelpazesinin varlığı bu kitabın kapsamlı ve güncel olması yönünde bize yol haritası olmuştur. Aile hekimliğinin, kendi eğitim içeriği, araştırmaları, kanıta dayalı ve klinik uygulamaları olan akademik ve bilimsel bir disiplin ve birinci basamağa odaklı bir klinik uzmanlık modeli ile konuların bilimsel ve pragmatik düzenlemesi yapılarak akışı sağlanmış, bilgilerin sistematik anlatımı kitap içerisinde planlanmıştır.


  • Open Access

    Treatment with biologic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients

    by Hazan Karadeniz, Hakan Babaoğlu, Aslıhan Avanoğlu Güler, Reyhan Bilici Salman, Hasan Satış, Nuh Ataş, Berna Göker, Şeminur Haznedaroğlu, Mehmet Akif Öztürk, Abdurrahman Tufan, et al.

    Objective: Lung nodules (LNs) impose diagnostic and therapeutic challenges in patients with rheuma- toid arthritis (RA) due to unpredictable outcomes. Potential induction of nodulosis with the use of con- ventional synthetic DMARDs (csDMARD) and lack of knowledge regarding the effect of biologic disease-modifying anti-rheumatic drugs (bDMARDs)/tofacitinib on the LN raise concerns and have an impact on treatment decisions. This study aims to evaluate the possible effects of the bDMARDs/tofa- citinib and csDMARDS on LNs observed in RA patients. Methods: Electronic health records of RA patients who had LNs detected on computed tomography (CT) between January 2015 and December 2020 were evaluated retrospectively. Patients with follow- up CT images were included in the study. Baseline and follow-up images were meticulously examined for the number, size, attenuation, and cavity formation. Clinical, histopathologic, and laboratory find- ings were analyzed. Results: Forty-two RA patients with LNs were studied, 21 were on bDMARDs/tofacitinib (11 females, mean age: 59.7 6 8.4) and 21 were on csDMARDs (12 females, mean age: 71.4 6 8.3). The proportion of patients with progressed nodules during follow-up was comparable between groups (six patients in bDMARDs/tofacitinib vs seven patients in csDMARDs). Progression of LNs was observed in six patients in the bDMARDs/tofacitinib group: three in anti-TNFa, two in rituximab, and one in abatacept users and none in tofacitinib users. Conclusion: Our results suggest that the risk of progression in LNs in RA patients with use of bDMARDs/tofacitinib might not impose a higher risk compared to csDMARDs. Moreover, bDMARDs/ tofacitinib might result in regression in LNs. Cite this article as: Karadeniz H, Cindil E, Babaog ̆ lu H, et al. Treatment with bio- logic DMARDs may not adversely affect lung nodules in rheumatoid arthritis patients. Eur J Rheumatol. 2022;9(2):75-81.


  • Open Access

    Diagnostic utility of serum biomarkers in large vessel vasculitis and their correlation with positron emission tomography

    by Reyhan Bilici Salman, Gülce Koca, Seda Gülbahar Ateş, Dilek Yapar, Hakan Babaoglu, Hasan Satış, Aslıhan Avanoglu Güler, Hazan Karadeniz, Nuh Ataş, Hamit Küçük, et al.

    To investigate the association between vascular inflammation, as detected by positron emission tomography (PET) imaging and interleukin-6 (IL-6), pentraxin3, and B-cell-activating factor (BAFF) in subjects with LVV. The study included newly diagnosed giant cell arteritis (GCA, n = 27) or Takayasu arteritis (n = 9) patients and healthy control (HC, n = 31) subjects. PET scan and blood samples were obtained before the introduction of treatments. IL-6, PTX3, and BAFF levels were determined quantitatively by enzyme-linked immunosorbent assay kits. Thirty-six patients with LVV (20 females, 16 males; age 64.5 ± 16.6 years) and 31 HC (14 females, 17 males; age 37.1 ± 9.6 years) were included. Serum levels of IL-6, PTX3, and BAFF were increased in patients with newly diagnosed LVV compared with healthy control subjects. In receiver operating characteristics (ROC) analysis, serum IL-6 and BAFF provided excellent discrimination of newly diagnosed LVV patients from HC (area under the ROC curve of >0.90 and >0.80, respectively). None of the inflammatory markers correlated with vascular inflammatory activity determined by PET scanning. Our results suggest that IL-6 and BAFF may serve as markers of large vessel vasculitis, while PTX3 is not useful. None of the inflammatory markers correlated with PET assessed vasculitis activity.